Immunome (IMNM) Accumulated Expenses (2019 - 2026)

Immunome (IMNM) has 8 years of Accumulated Expenses data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Accumulated Expenses fell 82.62% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 82.62% YoY) and the FY2025 annual result came in at $41.7 million, up 610.65% from the prior year.
• Accumulated Expenses retreated to $3.1 million in Q1 2026, from $41.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $41.7 million in Q4 2025 to a low of $827000.0 in Q1 2023.
• A 5-year average of $10.0 million and a median of $5.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 85.78% — and 2024, when it soared 1812.2%.
• Tracing IMNM's Accumulated Expenses over 5 years: stood at $4.9 million in 2022, then tumbled by 44.55% to $2.7 million in 2023, then soared by 114.37% to $5.9 million in 2024, then jumped by 610.65% to $41.7 million in 2025, then slumped by 92.63% to $3.1 million in 2026.
• The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $41.7 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.